{
  "docId": "019de075-4481-714f-9573-a4ad96e0f148",
  "docSlug": "816ee2fbc8fb2bf52edc4f2891aaa98f",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 27 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 6,
  "pageCount": 27,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "Highlights the repurposing of the active ingredient in Viagra for a new indication with no current FDA-approved treatments.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4481-714f-9573-a4ad96e0f148/6",
  "deckHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148",
  "deckJsonHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148.json",
  "deckAnchorHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.145,
        "w": 0.758,
        "x": 0.121,
        "y": 0.413
      },
      "kind": "list",
      "text": "Investigational cream formulation of sildenafil, the active ingredient in Viagra®, for topical administration to treat FSAD. A PDE5 inhibitor utilized in ED medications for men – ED product Viagra® peaked at $2.05 billion in sales in 2012. Designed to increase local blood flow to provide improvement in genital arousal response. Applied topically, avoiding hepatic first-pass metabolism response, resulting in lower systemic exposure potentially resulting in reduced side effects vs. oral sildenafil, including Viagra®.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d510562-df98-4aac-827d-641f1f535849",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.032,
        "w": 0.758,
        "x": 0.121,
        "y": 0.595
      },
      "kind": "list",
      "text": "FSAD is a physiological condition characterized by the inability to attain or maintain sufficient genital arousal during sexual activity. There are currently no FDA-approved treatments.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df62eec8-a756-4f23-8e84-bf90ae39a1c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.048,
        "w": 0.758,
        "x": 0.121,
        "y": 0.647
      },
      "kind": "list",
      "text": "Of the various types of female sexual dysfunction disorders, FSAD is most analogous to erectile dysfunction in men. Given similarities between ED and FSAD, sildenafil - the active ingredient in Viagra® - may improve genital arousal response and overall sexual experience for women as it does in men.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e75fafda-b2ef-447e-8edf-d47252e38582",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.032,
        "w": 0.758,
        "x": 0.121,
        "y": 0.361
      },
      "kind": "paragraph",
      "text": "Topically administered investigational Sildenafil Cream¹ is a potential first-in-category treatment for female sexual arousal disorder (FSAD)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0373e69f-990e-4cdf-a564-e8aafeddf19e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.305,
        "x": 0.056,
        "y": 0.751
      },
      "kind": "source-note",
      "text": "^505(b)(2) regulatory pathway anticipated. 1. Sildenafil Cream, 3.6% (formerly SST-6007) 2. https://qz.com/quartzy/1238782/its-the-20th-anniversary-of-viagra-heres-how-its-changed-the-world/#:~:text=Annual%20sales%20of%20Viagra%20peaked%20at%202.05%20billion%20in%202012.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecd1fa7e-43ec-4dfe-a77c-3398da86fa29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.028,
        "w": 0.426,
        "x": 0.287,
        "y": 0.195
      },
      "kind": "title",
      "text": "Advancing Products Women Want",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f40e9710-75df-4ee0-b316-411b96c6f5c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.036,
        "w": 0.272,
        "x": 0.364,
        "y": 0.288
      },
      "kind": "title",
      "text": "Sildenafil Cream, 3.6%^ Female Sexual Arousal Disorder",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecad06ab-6834-4886-a09d-319fce93a635",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem-Agitate-Solve (PAS)",
      "slug": "problem-agitate-solve-pas",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "eebf01af-3e8f-4250-95ea-dca96a445e03",
      "evidence": "Female Sexual Arousal Disorder (FSAD), which has no FDA-approved therapies",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 5,
      "beatId": "2c5920f7-d0be-4a45-91b2-e8b21c654a72",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 5-7 present Sildenafil Cream, 3.6% as a potential solution for FSAD",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}